Galectin Therapeutics (NASDAQ:GALT) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Get Rating) in a research report report published on Friday morning. The brokerage issued a sell rating on the stock.

Several other analysts have also recently issued reports on the company. Zacks Investment Research raised Galectin Therapeutics from a sell rating to a hold rating in a research report on Wednesday, January 19th. HC Wainwright reissued a buy rating on shares of Galectin Therapeutics in a research report on Friday, April 1st.

Shares of NASDAQ GALT opened at $1.74 on Friday. The company has a current ratio of 4.63, a quick ratio of 4.63 and a debt-to-equity ratio of 79.37. The stock has a market capitalization of $103.25 million, a PE ratio of -3.35 and a beta of 1.72. The stock’s fifty day simple moving average is $1.82 and its two-hundred day simple moving average is $2.37. Galectin Therapeutics has a 12-month low of $1.50 and a 12-month high of $5.70.

Galectin Therapeutics (NASDAQ:GALT – Get Rating) last announced its earnings results on Thursday, March 31st. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.07. On average, equities analysts predict that Galectin Therapeutics will post -0.42 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Galectin Therapeutics by 0.7% in the 4th quarter. BlackRock Inc. now owns 793,025 shares of the company’s stock worth $1,642,000 after purchasing an additional 5,443 shares in the last quarter. Virtu Financial LLC acquired a new stake in Galectin Therapeutics during the 4th quarter worth about $37,000. Synovus Financial Corp acquired a new stake in Galectin Therapeutics during the 4th quarter worth about $99,000. Millennium Management LLC lifted its position in Galectin Therapeutics by 15.8% during the 4th quarter. Millennium Management LLC now owns 405,601 shares of the company’s stock worth $840,000 after acquiring an additional 55,265 shares during the period. Finally, Geode Capital Management LLC lifted its position in Galectin Therapeutics by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 559,728 shares of the company’s stock worth $1,158,000 after acquiring an additional 18,862 shares during the period. 12.25% of the stock is owned by hedge funds and other institutional investors.

Galectin Therapeutics Company Profile (Get Rating)

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

See Also